- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01917370
VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (icc)
August 5, 2013 updated by: Ming Kuang,MD,PhD, First Affiliated Hospital, Sun Yat-Sen University
VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF
The investigators study the VEGF signaling in ICC cell lines/human tissues and its mechanism in HCC growth, proliferation and apoptosis.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Several studies have documented the elevated expression of VEGF and its receptors in ICC cell lines and tumor tissues.
Another study observed that the elevation of VEGF promotes the growth.
Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis.
However, few studies have been conducted to investigate the VEGF signaling in ICC cells and its possible mechanism in regulating ICC growth.Therefore,we try to clarify the mechanism of VEGF signal in ICC growth,proliferation and apoptosis.
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- First Affiliated Hospital, Sun Yat-Sen University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 90 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
intrahepatic cholangiocarcinoma patients underwent surgical therapy
Description
Inclusion Criteria:
- hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of intrahepatic cholangiocarcinoma and CA199>100U/L;or two or more dynamic imagine with a diagnosis of intrahepatic cholangiocarcinoma
- Child-Pugh A or B
- well preserved renal and hematopoietic Function
- receive complete surgical therapy
- achieve complete section accessed by contrast-enhanced CT
Exclusion Criteria:
- incomplete section
- Child-Pugh C
- combination with other hepatobiliary disease
- suffer from other tumors concurrently or in last five years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ICC patients
patients with intrahepatic cholangiocarcinoma treated by surgical treatment
|
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.
Time Frame: the day when conducting surgery (day 1)
|
the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have).
|
the day when conducting surgery (day 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ming Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Anticipated)
December 1, 2013
Study Completion (Anticipated)
December 1, 2014
Study Registration Dates
First Submitted
August 5, 2013
First Submitted That Met QC Criteria
August 5, 2013
First Posted (Estimate)
August 6, 2013
Study Record Updates
Last Update Posted (Estimate)
August 6, 2013
Last Update Submitted That Met QC Criteria
August 5, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- k0113011-2013ICC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrahepatic Cholangiocarcinoma
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Massachusetts General HospitalTerminatedResectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)TerminatedStage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic CholangiocarcinomaUnited States, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnBile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic CholangiocarcinomaUnited States
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingIntrahepatic Cholangiocarcinoma (ICC)China
Clinical Trials on surgical treatment
-
HealthCore-NERIUniversity of California, San Diego; University of Maryland; University of Alabama... and other collaboratorsTerminated
-
Peking University Third HospitalRecruitingOsteoarthritis, Knee | Anterior Cruciate Ligament RuptureChina
-
Uppsala UniversityCompletedSpinal Fractures
-
Kolding SygehusOdense University Hospital; Karolinska University Hospital; Zealand University... and other collaboratorsRecruitingFracture Humerus of ShaftSweden, Finland, Denmark, Norway
-
Sahlgrenska University Hospital, SwedenActive, not recruitingRupture | Ultrasonography | Acute Disease | Athletic Injuries | Achilles Tendon RuptureSweden
-
Medtronic Neurovascular Clinical AffairsRecruiting
-
AO Innovation Translation CenterRecruitingLong Bone FracturesUnited States, Canada, Australia, Ghana, Chile, China, Germany, India, Pakistan, Venezuela, Spain, Croatia, Greece
-
AO Clinical Investigation and Publishing DocumentationActive, not recruitingFemoral Shaft FractureUnited States, Canada, Switzerland, Germany, Austria
-
Hospital Severo OchoaCompleted
-
University of CologneCompletedOutcome, Fatal | Vertebral Osteomyelitis | Spondylodiscitis